Aadel A. Chaudhuri

Washington University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (32)

Purpose: Relapse is a major cause of failure in human papillomavirus–independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains (“lymph”) 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. Experimental Design: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(–) patients. Results: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. Conclusions: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus–independent head and neck squamous cell carcinoma.

Year:

2026

STables 1-9: STable 1: H&N Panel regions. STable 2: Covariate analysis of cohort. STables 3 & 4: COX regression analysis. STables 5-7: Cohort Characteristics. STable 8: Lymph sequencing metrics. STable 9: Tumor mutations by patient.

Year:

2026

Purpose: Relapse is a major cause of failure in human papillomavirus–independent head and neck squamous cell carcinoma. Clinicopathologic criteria for adjuvant treatment remain imprecise and have not changed for decades. We investigated whether ctDNA in lymphatic exudate collected via surgical drains (“lymph”) 24 hours after surgery identified molecular residual disease (MRD) and compared its performance with time-matched plasma. Experimental Design: Using an ultra-sensitive tumor-informed sequencing approach, tumor variants were called in lymph and plasma to classify patients as ctDNA positive or ctDNA negative, trained in an initial cohort of 36 patients, and replicated in an independent cohort of 37 patients. Progression-free survival was compared in ctDNA(+) versus ctDNA(–) patients. Results: Lymph identified MRD in two independent multi-site cohorts (initial cohort sensitivity = 76% and specificity = 63%; log-rank P = 0.01; replication cohort sensitivity = 65% and specificity = 70%; log-rank P = 0.04). Lymph performance was enhanced in locoregional relapse (sensitivity = 78% and specificity = 67%; log-rank P = 0.0004) and generalized to early-stage patients. Analysis of matched plasma collected at this early timepoint was not predictive of recurrence (sensitivity = 35% and specificity = 72%; log-rank P = 0.7). In patients with intermediate-risk pathology, lymph ctDNA was associated with recurrence (sensitivity = 88% and specificity = 67%; log-rank P = 0.0008), suggesting an opportunity for improved stratification of patients who may benefit from additional adjuvant treatment. Conclusions: Postoperative lymph is a novel, proximal, and early source of MRD with the potential to introduce more precision into adjuvant therapy decision-making and improve outcomes, especially for patients with intermediate-risk human papillomavirus–independent head and neck squamous cell carcinoma.

Year:

2025

Figures showing the CONSORT diagram, clonal hematopoiesis prevalence, the SNV score model, mid-chemoradiation ctDNA analysis, radiomic model robustness, pre-chemoradiation prognostic factors, association of clonal hematopoiesis with outcomes, and association of the CIRI-LCRT model with progression-free survival.

Year:

2025

The complementarity and clinical utility of combining liquid biopsies and radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) is highly prognostic, but on-treatment biomarkers are needed to enable response-adapted therapies. In this study, we analyzed 418 patients with NSCLC undergoing CRT to develop and validate a novel dynamic risk model that accurately predicts ultimate progression-free survival during treatment. We optimize tissue-free variant calling from plasma samples to facilitate ctDNA monitoring and demonstrate the importance of accounting for persistent clonal hematopoiesis variants. We show that mid-CRT ctDNA concentration is prognostic for disease progression and integrate additional pre-CRT risk factors, including radiomics, into a combined model that improves outcome prediction. Our results suggest that tumor features, radiomics, and mid-CRT ctDNA analysis are complementary and can identify patients at high and low risk of progression to potentially enable response-adapted therapies. Significance: This study demonstrates that combining tumor features, radiomics, and ctDNA analysis improves outcome prediction in NSCLC treated with CRT therapy. Our integrated model could enable personalized and response-adapted therapies to reduce toxicity and improve outcomes in patients. See related commentary by Anagnostou and Aggarwal, p. 1534

Year:

2025

Purpose: Two randomized clinical trials (STOMP and ORIOLE) demonstrated that stereotactic ablative radiotherapy (SABR) can prolong androgen-deprivation therapy–free survival or progression-free survival (PFS) in patients with metachronous oligometastatic castration-sensitive prostate cancer (omCSPC). Although most patients with omCSPC have a more modest delay in progression, a small subset achieves a durable response following SABR. We investigated the prognostic and predictive value of circulating prostate-specific membrane antigen-positive (PSMA + ) extracellular vesicles (EV) and PSA in a biomarker correlative study using blood samples from three independent patient cohorts. Experimental Design: Plasma samples from 46 patients with omCSPC on the ORIOLE trial and 127 patients with omCSPC on the STOMP trial protocol treated with SABR were included in the study. Pre-SABR PSMA + EV levels (EV/mL) were measured by nanoscale flow cytometry. Kaplan–Meier curves and logistic regression models were used to determine the association of PSMA + EV and PSA levels with clinical outcomes. Results: In the pooled cohorts, the median biochemical PFS were 26.1 and 15.0 months ( P = 0.005), and the median radiographic PFS were 36.0 and 25.0 months ( P = 0.003) for PSMA + EV-low and -high groups, respectively. The combination of pre-SABR low levels of both PSMA + EV and PSA was associated with a lower risk of radiographic progression (HR, 0.34, 95% confidence interval, 0.18–0.58; P = 0.0002). In the ORIOLE cohort, which included both an SABR arm and an observation arm, low PSMA + EV was predictive of benefit from SABR ( P = 0.012). Conclusions: PSMA + EV is a novel prognostic and predictive biomarker of radiographically occult tumor burden in omCSPC. PSMA + EV may inform clinical decisions about identifying patients who will achieve a durable benefit from consolidative SABR alone.

Year:

2025

Supplementary Figure S11. Cell-free DNA methylation levels of the top 10 least stem-like signature genes in plasma. The box and whisker plots summarize the promoter methylation rates for the top 10 least stem-like genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.

Year:

2025

Supplementary Figure S7. Distribution of differentially methylated regions in mCRPC plasma cell-free DNA. (A) Distribution of hypomethylated and hypermethylated genic DMRs in pre-treatment plasma cfDNA in AR /enhancer altered lethal mCRPC (compared to AR /enhancer wild-type mCRPC). (B) Genomic annotation of genic DMRs based on their location in the genome. (C) Top 50 hypermethylated DMRs found in pre-treatment plasma cfDNA from AR /enhancer altered lethal mCRPC patients (compared to AR /enhancer wild-type mCRPC). cfDNA, cell-free DNA; CDS, coding sequence; DMRs, differentially methylated regions; mCRPC, metastatic castration-resistant prostate cancer; UTR, untranslated region.

Year:

2025

Supplementary Figure S2. Kaplan-Meier analysis based on plasma collected prior to first-line androgen receptor-signaling inhibitor (ARSI) treatment according to (A,B) Androgen receptor ( AR ) gene body status and (C,D) AR enhancer region status in 63 patients with metastatic castration-resistant prostate cancer (mCRPC). p values were calculated by the log-rank test and hazard ratios (HRs) by the Mantel-Haenszel method.

Year:

2025

Supplementary Figure S10. Cell-free DNA methylation levels of the top 10 most stem-like signature genes in plasma. The box and whisker plots summarize promoter methylation rates for the top 10 most stem-like signature genes in plasma cfDNA from AR /enhancer altered versus wild-type mCRPC patients. p values were calculated by the Student’s t test. cfDNA, cell-free DNA; mCRPC, metastatic castration-resistant prostate cancer; TF, transcription factor.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (51)

Oliver Sartor

Tulane University School of Medicine

UNITED STATES
View details

AeRang Kim

Professor of Pediatrics

George Washington University

UNITED STATES
View details

Heath Skinner

Professor & Chair

University of Pittsburgh

UNITED STATES
View details

Christine A Pratilas

Vice Chair for Pediatric Oncology

Johns Hopkins University School of Medicine

UNITED STATES
View details

David Chen

Assistant Professor

Washington University in Saint Louis School of Medicine

UNITED STATES
View details

Russell Taylor Sundby

Assistant Professor

Thomas Jefferson University

UNITED STATES
View details

Sean Park

Professor

Mayo Clinic Rochester

UNITED STATES
View details

Phuoc T. Tran

University of Maryland

UNITED STATES
View details

Aaron Newman

Associate Professor

Stanford University

UNITED STATES
View details

Yufei Liu

Assistant Clinical Professor

City of Hope

UNITED STATES
View details

Jin Zhang

Associate Professor

Washington University in St. Louis

UNITED STATES
View details

Paul Jones

Washington University in St. Louis

UNITED STATES
View details

Everett J. Moding

Stanford University

UNITED STATES
View details

Ross A Okimoto

University of California

UNITED STATES
View details

Ruijiang Li

Associate Professor

Stanford University

UNITED STATES
View details

James Zou

Stanford University

UNITED STATES
View details

Jeffrey Szymanski

Assistant Professor

Mayo Clinic Minnesota

UNITED STATES
View details

Zhenqin Wu

Assistant Professor

The University of Hong Kong

HONG KONG
View details

Jace Webster

Full Specialist

University of California, San Francisco

UNITED STATES
View details

Tej D. Azad

Johns Hopkins University School of Medicine

UNITED STATES
View details

Arash Ash Alizadeh

Professor of Medicine

Stanford University School of Medicine

UNITED STATES
View details

Maximilian Diehn

Professor

Stanford University

UNITED STATES
View details

Piet Ost

Ghent University

BELGIUM
View details

Kavitha Ramchandran

Clinical Associate Professor

Stanford University

UNITED STATES
View details

Peter Harris

Staff Scientist

Washington University in St. Louis

UNITED STATES
View details

Jacob Orme

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Angela C. Hirbe

Washington University School of Medicine

UNITED STATES
View details

Andrea Gross

Associate Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Matthew E. Spector

University of Pittsburgh Medical Center

UNITED STATES
View details

Steven Lin

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Ryan C. Fields

University of Rochester

UNITED STATES
View details

Heather Wakelee

Professor

Stanford University

UNITED STATES
View details

Jack Shern

Head, Tumor Evolution and Genomics Section

National Institutes of Health

UNITED STATES
View details

Pradeep Chauhan

Assistant Professor

Mayo Clinic

UNITED STATES
View details

Seema Nagpal

-

UNITED STATES
View details

Sidharth V. Puram

Washington University School of Medicine

UNITED STATES
View details

David Kurtz

Assistant Professor

Stanford University

UNITED STATES
View details

Fabrice Lucien

Assistant Professor

Mayo Clinic Minnesota

UNITED STATES
View details

Jose P. Zevallos

University of Pittsburgh Medical Center

UNITED STATES
View details

Russell K. Pachynski

Washington University School of Medicine

UNITED STATES
View details

Billy Loo

Professor

Stanford University

UNITED STATES
View details

Trever Bivona

Professor

University of California, San Francisco

UNITED STATES
View details

John S A Chrisinger

Washington University in St. Louis

UNITED STATES
View details

Mohammed Abuul Usmani

Senior Scientist

Washington University in St. Louis

UNITED STATES
View details

Michael F. Gensheimer

Stanford University School of Medicine

UNITED STATES
View details

Robert Ferris

UPMC Endowed Professor

University of Pittsburgh School of Medicine

UNITED STATES
View details

Carina A Dehner

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Christopher A Maher

Washington University in St. Louis

UNITED STATES
View details

Wade Thorstad

Professor

Washington University School of Medicine

UNITED STATES
View details

Mohammad Shahrokh Esfahani

Assistant Professor

Stanford University

UNITED STATES
View details

Amy Armstrong

Associate Professor in Pediatrics

Washington University Physicians

UNITED STATES
View details